Legal & General Group
BDTX icon

Legal & General Group’s Black Diamond Therapeutics BDTX Stock Holding History

Legal & General Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,825
Closed -$5.93K – 3431
2025
Q1 		$5.93K Hold
3,825
– – ﹤0.01% 3253
2024
Q4 		$8.19K Hold
3,825
– – ﹤0.01% 3287
2024
Q3 		$16.6K Hold
3,825
– – ﹤0.01% 3120
2024
Q2 		$17.7K Buy
+3,825
New +$20.5K ﹤0.01% 3071
2022
Q2 		– Sell
-1,815
Closed -$5K – 3534
2022
Q1 		$5K Hold
1,815
– – ﹤0.01% 3500
2021
Q4 		$10K Sell
1,815
-4,653
-72% -$32.5K ﹤0.01% 3458
2021
Q3 		$54K Buy
6,468
+4,269
+194% +$42.2K ﹤0.01% 2954
2021
Q2 		$27K Sell
2,199
-786
-26% -$15.5K ﹤0.01% 3171
2021
Q1 		$72K Buy
2,985
+446
+18% +$12K ﹤0.01% 2706
2020
Q4 		$81K Hold
2,539
– – ﹤0.01% 2643
2020
Q3 		$77K Buy
2,539
+165
+7% +$5.02K ﹤0.01% 2563
2020
Q2 		$100K Buy
2,374
+504
+27% +$18.5K ﹤0.01% 2533
2020
Q1 		$45K Buy
+1,870
New +$56.9K ﹤0.01% 2619

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Legal & General Group's BDTX Position: Q2 2025 in Review

Legal & General Group sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 3,825 shares — an estimated $5.93K sold.

Legal & General Group first reported a position in BDTX in Q1 2020 and held it in 13 quarters. The position peaked at $100K in Q2 2020. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Legal & General Group reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 3,825 Black Diamond Therapeutics shares in Q2 2025, an estimated $5.93K.
  • Legal & General Group first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 13 quarters.
  • Legal & General Group's Black Diamond Therapeutics position peaked at $100K in Q2 2020.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.